High plasma sST2 levels in gastric cancer and their association with metastatic disease

Cancer Biomarkers

Volumn 16, Issue 1, 2016, Pages 117-125

  Bergis, Dominik ^a   Kassis, Valentin ^a   Radeke, Heinfried H ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Gastric cancer; Helicobacter pylori; Inflammation; Interleukin 33; SST2

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE RECEPTOR; INTERLEUKIN 33; INTERLEUKIN 33 SOLUBLE RECEPTOR; UNCLASSIFIED DRUG; AUTACOID; BACTERIUM ANTIBODY; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; CYTOKINE; IL1RL1 PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTRITIS; HELICOBACTER INFECTION; HISTOLOGY; HUMAN; HUMAN TISSUE; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; STOMACH ADENOCARCINOMA; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; BLOOD; CASE CONTROL STUDY; HELICOBACTER PYLORI; IMMUNOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; STOMACH TUMOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, BACTERIAL; BIOMARKERS; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; HELICOBACTER PYLORI; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-1 RECEPTOR-LIKE 1 PROTEIN; INTERLEUKIN-33; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, CELL SURFACE; ROC CURVE; STOMACH NEOPLASMS; YOUNG ADULT;

EID: 84956805245     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-150547     Document Type: Article

References (41)

1. S. Nagini, Carcinoma of the stomach: A review of epidemiology, pathogenesis, molecular genetics and chemoprevention, World J Gastrointest Oncol 4 (2012), 156-69.
2. P. Bertuccio, L. Chatenoud, F. Levi, D. Praud, J. Ferlay, E. Negri, M. Malvezzi and C. La Vecchia, Recent patterns in gastric cancer: A global overview, Int J Cancer 125 (2009), 666-73.
3. M. Pera, Epidemiology of esophageal cancer, especially adenocarcinoma of the esophagus and esophagogastric junction, Recent Results Cancer Res 155 (2000), 1-14.
4. K. F. Trivers, S. A. Sabatino and S. L. Stewart, Trends in esophageal cancer incidence by histology, United States, 1998-2003, Int J Cancer 123 (2008), 1422-8.
5. P. Lauren, The two histological main types of gastric carcinoma: Diffuse and so-calles intestinal type carcinoma. An attempt at a histo-clinical classification., Acta Pathol Microbiol Scand 64 (1965), 31-49.
6. J. R. Siewert and H. J. Stein, Classification of adenocarcinoma of the oesophagogastric junction, Br J Surg 85 (1998), 1457-9.
7. M. Asaka, H. Takeda, T. Sugiyama and M. Kato, What role does Helicobacter pylori play in gastric cancer Gastroenterology 113 (1997), S56-60.
8. N. Uemura, S. Okamoto, S. Yamamoto, N. Matsumura, S. Yamaguchi, M. Yamakido, K. Taniyama, N. Sasaki and R. J. Schlemper, Helicobacter pylori infection and the development of gastric cancer, N Engl J Med 345 (2001), 784-9.
9. S. Al-Haddad, A. C. Chang, G. De Hertogh, A. Grin, R. Langer, X. Sagaert, M. Salemme, C. J. Streutker, G. Soucy, M. Tripathi, M. P. Upton, M. Vieth and V. Villanacci, Adenocarcinoma at the gastroesophageal junction, Ann N Y Acad Sci 1325 (2014), 211-25.
10. P. Louis, G. L. Hold and H. J. Flint, The gut microbiota, bacterial metabolites and colorectal cancer, Nat Rev Microbiol 12 (2014), 661-72.
11. S. Rasch and H. Algul, A clinical perspective on the role of chronic inflammation in gastrointestinal cancer, Clin Exp Gastroenterol 7 (2014), 261-72.
12. J. Schmitz, A. Owyang, E. Oldham, Y. Song, E. Murphy, T. K. McClanahan, G. Zurawski, M. Moshrefi, J. Qin, X. Li, D. M. Gorman, J. F. Bazan and R. A. Kastelein, IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines, Immunity 23 (2005), 479-90.
13. Q. Liu and H. R. Turnquist, Implications for Interleukin-33 in solid organ transplantation, Cytokine 62 (2013), 183-94.
14. A. S. Mirchandani, R. J. Salmond and F. Y. Liew, Interleukin-33 and the function of innate lymphoid cells, Trends Immunol 33 (2012), 389-96.
15. E. Bourgeois, L. P. Van, M. Samson, S. Diem, A. Barra, S. Roga, J. M. Gombert, E. Schneider, M. Dy, P. Gourdy, J. P. Girard and A. Herbelin, The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFNgamma production, Eur J Immunol 39 (2009), 1046-55.
16. Q. Yang, G. Li, Y. Zhu, L. Liu, E. Chen, H. Turnquist, X. Zhang, O. J. Finn, X. Chen and B. Lu, IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8+ T cells, Eur J Immunol 41 (2011), 3351-60.
17. W. V. Bonilla, A. Frohlich, K. Senn, S. Kallert, M. Fernandez, S. Johnson, M. Kreutzfeldt, A. N. Hegazy, C. Schrick, P. G. Fallon, R. Klemenz, S. Nakae, H. Adler, D. Merkler, M. Lohning and D. D. Pinschewer, The alarmin interleukin-33 drives protective antiviral CD8(+) T cell responses, Science 335 (2012), 984-9.
18. C. Schiering, T. Krausgruber, A. Chomka, A. Frohlich, K. Adelmann, E. A. Wohlfert, J. Pott, T. Griseri, J. Bollrath, A. N. Hegazy, O. J. Harrison, B. M. Owens, M. Lohning, Y. Belkaid, P. G. Fallon and F. Powrie, The alarmin IL-33 promotes regulatory T-cell function in the intestine, Nature 513 (2014), 564-8.
19. M. Milovanovic, V. Volarevic, G. Radosavljevic, I. Jovanovic, N. Pejnovic, N. Arsenijevic and M. L. Lukic, IL-33/ST2 axis in inflammation and immunopathology, Immunol Res 52 (2012), 89-99.
20. C. Liu, Y. Zhang, J. Zhan, Y. Zhao, Q. Wan, H. Peng and W. Zhu, Interleukin-23A is associated with tumor growth in Helicobacter-pylori-related human gastric cancer, Cancer Cell Int 14 (2014), 104.
21. I. P. Jovanovic, N. N. Pejnovic, G. D. Radosavljevic, J. M. Pantic, M. Z. Milovanovic, N. N. Arsenijevic and M. L. Lukic, Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells, Int J Cancer 134 (2014), 1669-82.
22. Q. Xie and S. C. Wang, IL-33, an important biomarker in nonsmall-cell lung cancer, Asian Pac J Cancer Prev 14 (2013), 7763.
23. P. Sun, Q. Ben, S. Tu, W. Dong, X. Qi and Y. Wu, Serum interleukin-33 levels in patients with gastric cancer, Dig Dis Sci 56 (2011), 3596-601.
24. X. J. Chen, Y. D. Huang, N. Li,M. Chen, F. Liu, D. Pu and T. Y. Zhou, Correlations between serum IL33 and tumor development: a meta-analysis, Asian Pac J Cancer Prev 15 (2014), 3503-5.
25. A. F. Cutler, S. Havstad, C. K. Ma, M. J. Blaser, G. I. Perez-Perez and T. T. Schubert, Accuracy of invasive and noninvasive tests to diagnose Helicobacter pylori infection, Gastroenterology 109 (1995), 136-41.
26. L. Monteiro, A. de Mascarel, A. M. Sarrasqueta, B. Bergey, C. Barberis, P. Talby, D. Roux, L. Shouler, D. Goldfain, H. Lamouliatte and F. Megraud, Diagnosis of Helicobacter pylori infection: noninvasive methods compared to invasive methods and evaluation of two new tests, Am J Gastroenterol 96 (2001), 353-8.
27. C. A. Dinarello, An IL-1 family member requires caspase-1 processing and signals through the ST2 receptor, Immunity 23 (2005), 461-2.
28. D. Shao, F. Perros, G. Caramori, C. Meng, P. Dormuller, P. C. Chou, C. Church, A. Papi, P. Casolari, D. Welsh, A. Peacock, M. Humbert, I. M. Adcock and S. J. Wort, Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension, Biochem Biophys Res Commun 451 (2014), 8-14.
29. J. Gillibert-Duplantier, B. Duthey, V. Sisirak, D. Salaun, T. Gargi, O. Tredan, P. Finetti, F. Bertucci, D. Birnbaum, N. Bendriss-Vermare and A. Badache, Gene expression profilingx identifies sST2 as an effector of ErbB2-driven breast carcinoma cell motility, associated with metastasis, Oncogene 31 (2012), 3516-24.
30. D. Bergis, V. Kassis, A. Ranglack, V. Koeberle, A. Piiper, B. Kronenberger, S. Zeuzem, O. Waidmann and H. H. Radeke, High Serum Levels of the Interleukin-33 Receptor Soluble ST2 as a Negative Prognostic Factor in Hepatocellular Carcinoma, Transl Oncol 6 (2013), 311-8.
31. I. Jovanovic, G. Radosavljevic, M. Mitrovic, V. L. Juranic, A. N. McKenzie, N. Arsenijevic, S. Jonjic and M. L. Lukic, ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma, Eur J Immunol 41 (2011), 1902-12.
32. D. A. Pascual-Figal and J. L. Januzzi, The biology of ST2: the International ST2 Consensus Panel, Am J Cardiol 115 (2015), 3B-7B.
33. W. B. Cherry, J. Yoon, K. R. Bartemes, K. Iijima and H. Kita, A novel IL-1 family cytokine, IL-33, potently activates human eosinophils, J Allergy Clin Immunol 121 (2008), 1484-90.
34. J. I. Ellyard, L. Simson and C. R. Parish, Th2-mediated antitumour immunity: friend or foe, Tissue Antigens 70 (2007), 1-11.
35. K. Hung, R. Hayashi, A. Lafond-Walker, C. Lowenstein, D. Pardoll and H. Levitsky, The central role of CD4(+) T cells in the antitumor immune response, J Exp Med 188 (1998), 2357-68.
36. S. Tominaga, A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor, FEBS Lett 258 (1989), 301-4.
37. R. Klemenz, S. Hoffmann and A. K. Werenskiold, Serum-and oncoprotein-mediated induction of a gene with sequence similarity to the gene encoding carcinoembryonic antigen, Proc Natl Acad Sci U S A 86 (1989), 5708-12.
38. T. Hasegawa, M. Yashiro, T. Nishii, J. Matsuoka, Y. Fuyuhiro, T. Morisaki, T. Fukuoka, K. Shimizu, T. Shimizu, A. Miwa and K. Hirakawa, Cancer-associated fibroblasts might sustain the stemness of scirrhous gastric cancer cells via transforming growth factor-beta signaling, Int J Cancer 134 (2014), 1785-95.
39. J. Kurashige, K. Mima, G. Sawada, Y. Takahashi, H. Eguchi, K. Sugimachi, M. Mori, K. Yanagihara, M. Yashiro, K. Hirakawa, H. Baba and K. Mimori, Epigenetic modulation and repression of miR-200b by cancer-associated fibroblasts contribute to cancer invasion and peritoneal dissemination in gastric cancer, Carcinogenesis 36 (2015), 133-41.
40. K. Zhang, X. C. Zhang, Y. H. Mi and J. Liu, Predicting value of serum soluble ST2 and interleukin-33 for risk stratification and prognosis in patients with acute myocardial infarction, Chin Med J (Engl) 126 (2013), 3628-31.
41. L. Pastorelli, R. R. Garg, S. B. Hoang, L. Spina, B. Mattioli, M. Scarpa, C. Fiocchi, M. Vecchi and T. T. Pizarro, Epithelialderived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis, Proc Natl Acad Sci U S A 107 (2010), 8017-22.